Compare PubMatic Inc (PUBM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs GeneDx Holdings Corp — how do they compare? PubMatic Inc trades at $18.64 (market cap $850.88M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.4× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and GeneDx Holdings Corp for 19 Days on average.
| PUBM | WGS | |
|---|---|---|
Market Cap | $850.88M | $2.02B |
Volume | 997,698 | 734,640 |
Sector | Technology | Health |
52-Week High | $19.18 | $167.51 |
52-Week Low | $6.28 | $34.51 |
Typical Hold Time | 40 Days | 19 Days |
Enterprise Value | $754.01M | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUBM trades at $18.68, up 0.59% today, with a bullish technical signal supported by moving averages. The company reported a net loss of $14.46 million in 2025 despite revenue of $282.93 million, though recent quarters have shown earnings beats. Analyst sentiment is positive with a $19.89 consensus price target and 11 buy ratings. Recent news highlights AI-driven ad tech growth and leadership changes, including a new global chief revenue officer.
The outlook is cautiously optimistic given strong analyst support and technical momentum, but profitability challenges and competitive pressures in digital advertising pose risks. Revenue growth and margin improvement in higher-margin segments like mobile and CTV are key catalysts for upside, while execution risks and market volatility remain concerns.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
